![]() |
Name |
9H-Xanthen-9-one,3-hydroxy-3,6-dimethoxy-8-methyl
|
Molecular Formula | C16H14O5 | |
IUPAC Name* |
6-hydroxy-3,8-dimethoxy-1-methylxanthen-9-one
|
|
SMILES |
COc1cc(C)c2c(=O)c3c(OC)cc(O)cc3oc2c1
|
|
InChI |
InChI=1S/C16H14O5/c1-8-4-10(19-2)7-13-14(8)16(18)15-11(20-3)5-9(17)6-12(15)21-13/h4-7,17H,1-3H3
|
|
InChIKey |
OOBUSGFXVKYXAB-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 286.28 | ALogp: | 3.0 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 68.9 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.726 |
Caco-2 Permeability: | -4.861 | MDCK Permeability: | 0.00001730 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.926 |
Human Intestinal Absorption (HIA): | 0.017 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.234 |
Blood-Brain-Barrier Penetration (BBB): | 0.029 | Plasma Protein Binding (PPB): | 88.99% |
Volume Distribution (VD): | 1.017 | Fu: | 11.81% |
CYP1A2-inhibitor: | 0.968 | CYP1A2-substrate: | 0.968 |
CYP2C19-inhibitor: | 0.795 | CYP2C19-substrate: | 0.335 |
CYP2C9-inhibitor: | 0.663 | CYP2C9-substrate: | 0.939 |
CYP2D6-inhibitor: | 0.788 | CYP2D6-substrate: | 0.926 |
CYP3A4-inhibitor: | 0.611 | CYP3A4-substrate: | 0.196 |
Clearance (CL): | 5.63 | Half-life (T1/2): | 0.627 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.187 |
Drug-inuced Liver Injury (DILI): | 0.871 | AMES Toxicity: | 0.481 |
Rat Oral Acute Toxicity: | 0.096 | Maximum Recommended Daily Dose: | 0.858 |
Skin Sensitization: | 0.57 | Carcinogencity: | 0.028 |
Eye Corrosion: | 0.251 | Eye Irritation: | 0.982 |
Respiratory Toxicity: | 0.53 |